VYD222 (Invymab)
Prevention of COVID-19
Key Facts
About Invivyd
Invivyd's mission is to deliver protection from serious viral infectious diseases by developing rapidly-adaptable monoclonal antibody therapies. The company has achieved key milestones, including positive Phase 3 results for its COVID-19 candidate and an Emergency Use Authorization from the U.S. FDA. Its strategy leverages a proprietary, integrated technology platform to monitor viral evolution and engineer potent, variant-resistant antibodies, positioning it as a critical player in pandemic preparedness and the management of endemic viral diseases.
View full company profileAbout Invivyd
Invivyd's mission is to deliver protection from serious viral infectious diseases by developing rapidly-adaptable monoclonal antibody therapies. The company has achieved key milestones, including positive Phase 3 results for its COVID-19 candidate and an Emergency Use Authorization from the U.S. FDA. Its strategy leverages a proprietary, integrated technology platform to monitor viral evolution and engineer potent, variant-resistant antibodies, positioning it as a critical player in pandemic preparedness and the management of endemic viral diseases.
View full company profileTherapeutic Areas
Other Prevention of COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| SARS-CoV-2 Vaccine | Auro Vaccines | Poised for Clinical |
| OCU500 | Ocugen | IND Cleared |
| DMAb-1 / DMAb-2 | Inovio Pharmaceuticals | Phase 1 |